120 related articles for article (PubMed ID: 38529678)
1. Methylprednisolone Pulses and Prolonged Remission in Systemic Lupus Erythematosus: A Propensity Score Analysis of the Longitudinal Lupus-Cruces-Bordeaux Inception Cohort.
Ruiz-Irastorza G; Paredes-Ruiz D; Herrero-Galvan M; Moreno-Torres V; Hernandez-Negrin H; Ruiz-Arruza I; Leonard C; Richez C; Lazaro E
Arthritis Care Res (Hoboken); 2024 Mar; ():. PubMed ID: 38529678
[TBL] [Abstract][Full Text] [Related]
2. Prolonged remission in SLE is possible by using reduced doses of prednisone: An observational study from the Lupus-Cruces and Lupus-Bordeaux inception cohorts.
Ruiz-Irastorza G; Ruiz-Estevez B; Lazaro E; Ruiz-Arruza I; Duffau P; Martin-Cascon M; Richez C; Ugarte A; Blanco P
Autoimmun Rev; 2019 Sep; 18(9):102359. PubMed ID: 31323362
[TBL] [Abstract][Full Text] [Related]
3. Repeated pulses of methyl-prednisolone with reduced doses of prednisone improve the outcome of class III, IV and V lupus nephritis: An observational comparative study of the Lupus-Cruces and lupus-Bordeaux cohorts.
Ruiz-Irastorza G; Ugarte A; Saint-Pastou Terrier C; Lazaro E; Iza A; Couzi L; Saenz R; Richez C; Porta S; Blanco P
Autoimmun Rev; 2017 Aug; 16(8):826-832. PubMed ID: 28564619
[TBL] [Abstract][Full Text] [Related]
4. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval.
Loncharich MF; Anderson CW
ACR Open Rheumatol; 2022 Jun; 4(6):486-491. PubMed ID: 35157371
[TBL] [Abstract][Full Text] [Related]
5. Infections in newly diagnosed Spanish patients with systemic lupus erythematosus: data from the RELES cohort.
González-Echavarri C; Capdevila O; Espinosa G; Suárez S; Marín-Ballvé A; González-León R; Rodríguez-Carballeira M; Fonseca-Aizpuru E; Pinilla B; Pallarés L; Ruiz-Irastorza G;
Lupus; 2018 Dec; 27(14):2253-2261. PubMed ID: 30451641
[TBL] [Abstract][Full Text] [Related]
6. Both prolonged remission and Lupus Low Disease Activity State are associated with reduced damage accrual in systemic lupus erythematosus.
Tsang-A-Sjoe MW; Bultink IE; Heslinga M; Voskuyl AE
Rheumatology (Oxford); 2017 Jan; 56(1):121-128. PubMed ID: 27803306
[TBL] [Abstract][Full Text] [Related]
7. Prolonged clinical remission and low disease activity statuses are associated with better quality of life in systemic lupus erythematosus.
Poomsalood N; Narongroeknawin P; Chaiamnuay S; Asavatanabodee P; Pakchotanon R
Lupus; 2019 Sep; 28(10):1189-1196. PubMed ID: 31307256
[TBL] [Abstract][Full Text] [Related]
8. The administration of low doses of rituximab followed by hydroxychloroquine, prednisone and low doses of mycophenolate mofetil is an effective therapy in Latin American patients with active systemic lupus erythematosus.
Galarza-Maldonado C; Kourilovitch MR; Molineros JE; Cardiel MH; Zurita L; Soroka NF; Yagur VY; Doukh N; Cervera R
Autoimmun Rev; 2010 Dec; 10(2):108-11. PubMed ID: 20804861
[TBL] [Abstract][Full Text] [Related]
9. Restrictive Use of Oral Glucocorticoids in Systemic Lupus Erythematosus and Prevention of Damage Without Worsening Long-Term Disease Control: An Observational Study.
Ruiz-Arruza I; Lozano J; Cabezas-Rodriguez I; Medina JA; Ugarte A; Erdozain JG; Ruiz-Irastorza G
Arthritis Care Res (Hoboken); 2018 Apr; 70(4):582-591. PubMed ID: 28704598
[TBL] [Abstract][Full Text] [Related]
10. Remission and low disease activity (LDA) prevent damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort.
Ugarte-Gil MF; Hanly J; Urowitz M; Gordon C; Bae SC; Romero-Diaz J; Sanchez-Guerrero J; Bernatsky S; Clarke AE; Wallace DJ; Isenberg DA; Rahman A; Merrill JT; Fortin PR; Gladman DD; Bruce IN; Petri M; Ginzler EM; Dooley MA; Ramsey-Goldman R; Manzi S; Jönsen A; van Vollenhoven RF; Aranow C; Mackay M; Ruiz-Irastorza G; Lim S; Inanc M; Kalunian K; Jacobsen S; Peschken C; Kamen DL; Askanase A; Pons-Estel BA; Alarcón GS
Ann Rheum Dis; 2022 Nov; 81(11):1541-1548. PubMed ID: 35944946
[TBL] [Abstract][Full Text] [Related]
11. Comparison of high versus low-medium prednisone doses for the treatment of systemic lupus erythematosus patients with high activity at diagnosis.
Ruiz-Arruza I; Barbosa C; Ugarte A; Ruiz-Irastorza G
Autoimmun Rev; 2015 Oct; 14(10):875-9. PubMed ID: 26044819
[TBL] [Abstract][Full Text] [Related]
12. Clinical impact of hydroxychloroquine dose adjustment according to the American Academy of Ophthalmology guidelines in systemic lupus erythematosus.
Vázquez-Otero I; Medina-Cintrón N; Arroyo-Ávila M; González-Sepúlveda L; Vilá LM
Lupus Sci Med; 2020 May; 7(1):. PubMed ID: 32434863
[TBL] [Abstract][Full Text] [Related]
13. Impact of low disease activity, remission, and complete remission on flares following tapering of corticosteroids and immunosuppressive therapy in patients with systemic lupus erythematous: a multinational cohort study.
Cho J; Shen L; Huq M; Kandane-Rathnayake R; Golder V; Louthrenoo W; Chen YH; Hamijoyo L; Luo SF; Wu YJ; Zamora L; Li Z; Sockalingam S; Katsumata Y; Harigai M; Hao Y; Zhang Z; Basnayake D; Chan M; Kikuchi J; Takeuchi T; Bae SC; Oon S; O'Neill S; Goldblatt F; Ng KPL; Law A; Tugnet N; Kumar S; Tee C; Tee M; Ohkubo N; Tanaka Y; Navarra SV; Lau CS; Hoi A; Morand EF; Nikpour M; Lateef A;
Lancet Rheumatol; 2023 Oct; 5(10):e584-e593. PubMed ID: 38251484
[TBL] [Abstract][Full Text] [Related]
14. Long-Term Clinical Outcomes in a Cohort of Adults With Childhood-Onset Systemic Lupus Erythematosus.
Groot N; Shaikhani D; Teng YKO; de Leeuw K; Bijl M; Dolhain RJEM; Zirkzee E; Fritsch-Stork R; Bultink IEM; Kamphuis S
Arthritis Rheumatol; 2019 Feb; 71(2):290-301. PubMed ID: 30152151
[TBL] [Abstract][Full Text] [Related]
15. The influence of therapy on CD4+CD25(high)FOXP3+ regulatory T cells in systemic lupus erythematosus patients: a prospective study.
Tselios K; Sarantopoulos A; Gkougkourelas I; Boura P
Scand J Rheumatol; 2015; 44(1):29-35. PubMed ID: 25205084
[TBL] [Abstract][Full Text] [Related]
16. Discontinuation of hydroxychloroquine in older patients with systemic lupus erythematosus: a multicenter retrospective study.
Fernandez-Ruiz R; Bornkamp N; Kim MY; Askanase A; Zezon A; Tseng CE; Belmont HM; Saxena A; Salmon JE; Lockshin M; Buyon JP; Izmirly PM
Arthritis Res Ther; 2020 Aug; 22(1):191. PubMed ID: 32807233
[TBL] [Abstract][Full Text] [Related]
17. Disease course patterns in systemic lupus erythematosus.
Tselios K; Gladman DD; Touma Z; Su J; Anderson N; Urowitz MB
Lupus; 2019 Jan; 28(1):114-122. PubMed ID: 30526328
[TBL] [Abstract][Full Text] [Related]
18. Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) enables accurate and user-friendly definitions of clinical remission and categories of disease activity.
Jesus D; Larosa M; Henriques C; Matos A; Zen M; Tomé P; Alves V; Costa N; Le Guern V; Iaccarino L; Costedoat-Chalumeau N; Doria A; Inês LS
Ann Rheum Dis; 2021 Dec; 80(12):1568-1574. PubMed ID: 34407927
[TBL] [Abstract][Full Text] [Related]
19. Hydroxychloroquine Serum Concentrations and Flares of Systemic Lupus Erythematosus: A Longitudinal Cohort Analysis.
Mok CC; Penn HJ; Chan KL; Tse SM; Langman LJ; Jannetto PJ
Arthritis Care Res (Hoboken); 2016 Sep; 68(9):1295-302. PubMed ID: 26749299
[TBL] [Abstract][Full Text] [Related]
20. Which patients with systemic lupus erythematosus in remission can withdraw low dose steroids? Results from a single inception cohort study.
Fasano S; Coscia MA; Pierro L; Ciccia F
Lupus; 2021 May; 30(6):991-997. PubMed ID: 33709836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
